EN 简
EN 简

学术文献

标题

疾病领域

Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19
Annals of Internal Medicine
2023年4月18日

COVID-19
Preliminary Safety and Efficacy of the Combination Therapy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Treating Chronic HBV Infection
Presentation at the 2023 APASL
2023年2月18日

乙型肝炎
Safety, Tolerability, and Pharmacokinetics of BRII-778, A Modified-Release Oral Formulation of Rilpivirine in Healthy Adult Subjects
Presentation at IDWeek 2022
2022年10月21日

HIV
Safety, Tolerability, and Pharmacokinetics of BRII-732, A Medoxomil Carbonate Prodrug of Islatravir in Healthy Adult Subjects
Presentation at IDWeek 2022
2022年10月21日

HIV
Safety, Tolerability, and Pharmacokinetics of BRII-296, An Extended-Release Injectable Aqueous Suspension Formulation of Brexanolone in Healthy Adult Subjects
Presentation at the International Marcé Society Conference
2022年9月19日

PPD
Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2
Frontiers in Immunology
2022年9月14日

COVID-19
Amubarvimab/Romlusevimab: First Approval
Drugs
2022年8月23日

COVID-19
Safety and Antiviral Activity of Two Monthly Administration of BRII-835 (VIR-2218), an X-Targeting RNAi Therapeutic, in Chinese Patients with Chronic HBV Infection
Presentation at the 2022 APASL conference
2022年3月31日

乙型肝炎
Pharmacokinetic and Safety Phase 1 Study and Microneutralization Assay Results with BRII-196/BRII-198, a Novel Antibody Cocktail Active Against a Wide Range of SARS-CoV-2 Variants
Open Forum Infectious Diseases, IDWeek 2021 Abstracts
2021年12月04日

COVID-19
Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study
JHEP Reports
2021年9月07日

乙型肝炎
Phase 1 safety and pharmacokinetics studies of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies
medRxiv
2021年7月23日

COVID-19
Restoration of HBV-specific immune responses with therapeutic vaccine BRII-179 (VBI-2601) in chronic HBV patients in a phase 1b/2a study
Presentation at the 2021 EASL
2021年6月23日

乙型肝炎